Buy Ciprolet

Tablets covered with a film coat of white or almost white color, round, biconvex, with a smooth surface on both sides; on a fracture white or almost white mass.

1 tab.
ciprofloxacin hydrochloride 291.106 mg,
which corresponds to the content of ciprofloxacin 250 mg
Excipients: corn starch - 50.323 mg, microcrystalline cellulose - 7.486 mg, croscarmellose sodium - 10 mg, silicon colloidal dioxide - 5 mg, talc - 5 mg, magnesium stearate - 3.514 mg.

The composition of the membrane: hypromellose (6 cps) - 4.8 mg, sorbic acid 0.08 mg, titanium dioxide 2 mg, talc 1.6 mg, macrogol 6000-1.36 mg, polysorbate 80-0.08 mg, dimethicone 0.08 mg.

10 pieces. - blisters (1) - packs of cardboard.
10 pieces. - blisters (2) - packs of cardboard.

Tablets covered with a film coat of white or almost white color, round, biconvex, with a smooth surface on both sides; on the fracture - a white with a slightly yellowish hue mass.

1 tab.
ciprofloxacin hydrochloride 582.211 mg,
which corresponds to the content of ciprofloxacin 500 mg
Excipients: corn starch - 27.789 mg, microcrystalline cellulose - 5 mg, croscarmellose sodium - 20 mg, silicon colloidal dioxide - 5 mg, talc - 6 mg, magnesium stearate - 4.5 mg.

The composition of the membrane: hypromellose (6 cps) - 5 mg, sorbic acid - 0.072 mg, titanium dioxide - 1.784 mg, talc - 1.784 mg, macrogol 6000 - 1.216 mg, polysorbate 80 - 0.072 mg, dimethicone - 0.072 mg.

10 pieces. - blisters (1) - packs of cardboard.
10 pieces. - blisters (2) - packs of cardboard.

Antibacterial preparation of a broad spectrum of action from the group of fluoroquinolones. It is bactericidal. The drug inhibits the DNA enzyme enzyme of bacteria, as a result of which DNA replication and the synthesis of bacterial cell proteins are disturbed. Ciprofloxacin acts both on multiplying microorganisms, and on being in a rest phase.

Gram-negative aerobic bacteria are sensitive to ciprofloxacin: Escherichia coli, Salmonella spp., Shigella spp., Citrobacter spp., Klebsiella spp., Enterobacter spp., Proteus mirabilis, Proteus vulgaris, Serratia marcescens, Hafhia alvei, Edwardsiella tarda, Providencia spp., Morganella morganii, Vibrio spp., Yersinia spp .; other gram-negative bacteria: Haemophilus spp., Pseudomonas aeruginosa, Moraxella catarrhalis, Aeromonas spp., Pasteurella multocida, Plesiomonas shigelloides, Campylobacter jejuni, Neisseria spp .; some intracellular pathogens: Legionella pneumophila, Brucella spp., Chlamydia trachomatis, Listeria monocytogenes, Mycobacterium tuberculosis, Mycobacterium kansasii, Mycobacterium avium-intracellulare.

Gram-positive aerobic bacteria are also sensitive to ciprofloxacin: Staphylococcus spp. (S. aureus, S. haemolyticus, S. hominis, S.saprophyticus), Streptococcus spp. (St. pyogenes, St.agalactiae). The majority of staphylococci, resistant to methicillin, are resistant to ciprofloxacin.

The sensitivity of bacteria Streptococcus pneumoniae, Enterococcus faecalis is moderate.

The drug is resistant to Corynebacterium spp., Bacteroides fragilis, Pseudomonas cepacia, Pseudomonas maltophilia, Ureaplasma urealyticum, Clostridium difficile, Nocardia asteroides. The effect of the drug against Treponema pallidum has not been adequately studied.

When taken orally, ciprofloxacin is rapidly absorbed from the digestive tract. Bioavailability of the drug is 50-85%. Cmax of the drug in the blood serum of healthy volunteers after oral administration of the drug (before meals) at a dose of 250, 500, 750 and 1000 mg is achieved after 1-1.5 hours and is 1.2, 2.4, 4.3 and 5.4 μg / ml, respectively.

Orally taken ciprofloxacin is distributed in tissues and body fluids. High concentrations of the drug are observed in bile, lung, kidney, liver, gall bladder, uterus, seminal fluid, prostate tissue, tonsils, endometrium, fallopian tubes and ovaries. The concentration of the drug in these tissues is higher than in the serum. Ciprofloxacin also penetrates well into the bones, eye fluid, bronchial secretion, saliva, skin, muscles, pleura, peritoneum, lymph.

The accumulating concentration of ciprofloxacin in blood neutrophils is 2-7 times higher than in serum.

Vd in the body is 2-3.5 l / kg. In the cerebrospinal fluid the drug penetrates in a small amount, where its concentration is 6-10% of that of serum.

The degree of binding of ciprofloxacin to plasma proteins is 30%.

In patients with unchanged kidney function, T1 / 2 is usually 3-5 hours. The main way of removing ciprofloxacin from the body through the kidneys. With urine, 50-70% is output. From 15 to 30% is excreted with feces.

If there is a violation of kidney function, T1 / 2 increases.

Patients with severe renal insufficiency (CC below 20 ml / min / 1.73m2) should be prescribed half the daily dose of the drug.

Infectious-inflammatory diseases caused by microorganisms sensitive to ciprofloxacin, including:

- respiratory tract infections;

- infection of ENT organs;

- infections of the kidneys and urinary tract;

- genital infection;

- Gastrointestinal infections (including the mouth, teeth, jaws);

- infections of the gallbladder and bile ducts;

- infections of the skin, mucous membranes and soft tissues;

- infections of the musculoskeletal system;

- sepsis;

Peritonitis.

Prevention and treatment of infections in patients with reduced immunity (with immunosuppressant therapy).

- Pseudomembranous colitis;

- pregnancy;

- the period of lactation (breastfeeding);

- children and adolescence under 18;

- hypersensitivity to ciprofloxacin or other drugs from the group of fluoroquinolones.

With caution should prescribe the drug with severe arteriosclerosis of the cerebral vessels, cerebral circulation, mental illness, convulsive syndrome, epilepsy, severe renal and / or liver failure, and also elderly patients.

The dose of Ciprolet depends on the severity of the disease, type of infection, body condition, age, body weight and kidney function.

In uncomplicated diseases of the kidneys and urinary tract appoint 250 mg 2 times / day, and in severe cases - 500 mg 2 times / day.

In diseases of the lower respiratory tract of medium severity - 250 mg 2 times / day, and in more severe cases - 500 mg 2 times / day.

For the treatment of gonorrhea, a single dose of Ziprolet in a dose of 250-500 mg is recommended.

With gynecological diseases, enteritis and colitis with severe course and high fever, prostatitis, osteomyelitis, 500 mg 2 times / day are prescribed (for treatment of usual diarrhea, it can be used at a dose of 250 mg 2 times / day).

Tablets should be taken on an empty stomach, with plenty of fluids.

The duration of treatment depends on the severity of the disease, but treatment should always last at least 2 more days after the disappearance of the symptoms of the disease. Usually the duration of treatment is 7-10 days.

Patients with severe renal dysfunction should be given half the dose of the drug.

Table of recommended doses of the drug for patients with chronic renal failure:

Creatinine clearance (ml / min) Dose
> 50 Normal dosing regimen
30-50 250-500 mg once every 12 hours
5-29 250-500 mg once every 18 hours
Patients on hemo- or peritoneal dialysis after dialysis 250-500 mg once every 24 hours

On the part of the digestive system: nausea, diarrhea, vomiting, abdominal pain, flatulence, anorexia, cholestatic jaundice (especially in patients with liver disease), hepatitis, hepatonecrosis, increased liver transaminases and alkaline phosphatase.

From the side of the nervous system: dizziness, headache, fatigue, anxiety, tremor, insomnia, nightmares, peripheral paralysis (anomaly of perception of pain), sweating, increased intracranial pressure, anxiety, confusion, depression, hallucinations, and other manifestations psychotic reactions (occasionally progressing to conditions in which the patient can do harm to himself), migraine, fainting, thrombosis of the cerebral arteries.

From the senses: a violation of taste and smell, visual impairment (diplopia, change in color perception), noise in the ears, hearing loss.

From the cardiovascular system: tachycardia, heart rhythm disturbances, lowering blood pressure, flushing of blood to the skin of the face.

On the part of the hematopoiesis system: leukopenia, granulocytopenia, anemia, thrombocytopenia, leukocytosis, thrombocytosis, hemolytic anemia.

From the laboratory indicators: gipoprotrombinemiya, giperkreatininemiya, hyperbilirubinemia, hyperglycemia.

On the part of the urinary system: hematuria, crystalluria (especially in alkaline urine and low diuresis), glomerulonephritis, dysuria, polyuria, urinary retention, albuminuria, urethral bleeding, hematuria, decreased renal nitrogen function, interstitial nephritis.

Allergic reactions: skin itching, urticaria, blistering accompanied by bleeding, and small nodules forming scabs, drug fever, pinpoint hemorrhages, facial or laryngeal edema, dyspnea, eosinophilia, increased photosensitivity, vasculitis, nodal erythema, exudative erythema multiforme , Stevens-Johnson syndrome (malignant exudative erythema), toxic epidermal necrolysis (Lyell's syndrome).

From the musculoskeletal system: arthralgia, arthritis, tendovaginitis, tendon ruptures, myalgia.

Other: general weakness, superinfections (candidiasis, pseudomembranous colitis).

Treatment: it is necessary to carefully monitor the patient's condition, make gastric lavage, carry out usual emergency measures, ensure sufficient fluid intake. With the help of hemo- or peritoneal dialysis, only a small (less than 10%) amount of the drug can be excreted. The specific antidote is unknown.

With the simultaneous use of Ciprolet with didanosine, ciprofloxacin absorption decreases due to the formation of ciprofloxacin complexes with aluminum and magnesium salts contained in Didanosine.

Simultaneous administration of Ciprolet and theophylline may lead to an increase in the concentration of theophylline in the blood plasma, due to competitive inhibition in the binding sites of cytochrome P450, which leads to an increase in T1 / 2 theophylline and an increased risk of toxic effects associated with theophylline.

Simultaneous reception of antacids, as well as preparations containing ions of aluminum, zinc, iron or magnesium, can cause a decrease in absorption of ciprofloxacin, so the interval between the appointment of these drugs should be at least 4 hours.

With the simultaneous use of Ciprolet and anticoagulants, the bleeding time is prolonged.

With the simultaneous use of Ciprolet and cyclosporine, the nephrotoxic effect of the latter is enhanced.

Patients with epilepsy, seizures in the anamnesis, vascular diseases and organic brain lesions in connection with the threat of the development of adverse reactions from the central nervous system Tsiprolet should be prescribed only for vital indications.

If a severe and prolonged diarrhea occurs during or after treatment, the diagnosis of pseudomembranous colitis should be ruled out, which requires immediate discontinuation of the drug and the appointment of appropriate treatment.

If pain occurs in the tendons or when the first signs of tendovaginitis appear, treatment should be discontinued due to the fact that individual cases of inflammation and even rupture of tendons during treatment with fluoroquinolones are described.

During treatment with Ciprolet it is necessary to provide a sufficient amount of fluid while observing normal diuresis.

During treatment with Ciprolet should avoid contact with direct sunlight.

Impact on the ability to drive vehicles and manage mechanisms

Patients taking Ciprolet should be careful when driving a car and practicing other potentially dangerous activities that require increased attention and speed of psychomotor reactions (especially with simultaneous use of alcohol).

The drug is contraindicated for use in pregnancy and lactation.

The drug should be stored in a dry, protected from light, out of reach of children at a temperature of up to 25 ° C. Shelf life - 3 years.